updat model reflect management guidanc impli steeper back-
half ramp expect expect driven eas y/i comp relat
pharmedium progress ramp smith synergi see
low- mid-singl digit pharma op profit growth due stabl fundament
growth specialti continu benefit smith
management guidanc rel flat compar previou year period impli
steep back-half ramp street expect larg due headwind
relat pharmedium first-half lower contribut brand
compens progress y/i comp relat pharmedium eas
particularli result dampen closur
memphi facil lower unit ship open facil well due
implement enhanc qualiti procedur test addit synergi
 smith acquisit ramp also help drive back-
expect low- mid-singl digit oper profit growth pharma distribut
given guidanc low-singl digit despit headwind relat pharmedium
recal pharmedium headwind segment guidanc would
mid-singl digit growth addit mid-singl digit oper profit growth
exclud headwind pharmedium benefit smith
indic us core fundament pharma distribut remain stabl think
specialti continu drive top- bottom-lin growth appear
consider macro driver evidenc strong result pharma
past quarter furthermor continu realiz benefit
smith synergi expect reach steadi run-rat sometim
lower adj ep estim
respect lower price target slightli impli share trade
adj ep estim current multipl
pleas see page report import disclosur
posit think on-going transit custom new
price model break specialti result margin expans drive growth
profit addit sourc benefit wbad help drive margin
profit medium-term volum esrx onboard onboard
store acquir also serv near-term tailwind
 statu regard remedi effort
pharmedium
 progress fusion implement
 top-lin growth driven specialti
includ alliancerx acquisit hd
smith store acquir
 gross margin
 ebit margin
 top-lin growth high-teen due
greater expect growth specialti
contribut pharmedium
 gm due better
expect purchas effici
 sg better expect due
 share come lower due greater
expect share repo
 top-lin growth low-singl digit
due lower brand inflat
 margin closer due higher
expect gener deflat lower
 sg come wors expect
 share come higher due lower
one three largest pharmaceut distribut compani
 servic pharmaceut manufactur health care provid
pharmaceut suppli channel primarili provid drug distribut relat servic
distribut comprehens offer brand name gener pharmaceut over-the-
counter health care product home health care suppli equip wide varieti
health care provid locat throughout includ acut care hospit
health system independ chain retail pharmaci mail-ord facil physician
clinic altern site facil skill nurs assist live center
million except per-shar data
cowen compani
model assumptionstermin growth depreci chang work capit valuefre free futur excess number per end septemb cowen
million except per-shar data
compani report cowen compani
cost good gross margin ebitda ebit losses/ incom affili exp tax incom conv sub note deal-rel sever litig incom cont incom deal-rel incom ex-discontinu average ep ex discontinu chang incom cont ep cont end septemb cowen
million except per-shar data
compani report cowen compani
cost good gross margin ebitda ebit losses/ incom affili exp tax incom conv sub note deal-rel sever litig own net incom deal-rel incom ex-discontinu average ep ex-discontinu chang year-over-year total incom cont ep cont cowen
million
compani report cowen compani
asset receiv net doubt expens current charg total liabil account payabl incom current equiti common paid-in earn comprehens commmon stock total stockhold liabil stockhold liquid ratio current sale purchas acct ratio inventori structur long-term solvenc ratio total debt total interest ratio return commit capit asset averag stockhold equiti cowen
million
compani report cowen compani
income/ loss flow oper activ depreci provis loss account sale invest employe stock defer incom invest impair oper asset liabil account merchandis prepaid expens account payabl accru expens incom net cash oper acquisit properti acquisit purchas treasuri dividend common proceeds/ repay debt net increase/ decreas cash equival begin cash equival end summari oper year end septemb cowen
million
compani report cowen compani
activitiesnet loss incom discontinu incom continu adjust reconcil net incom provis loss account provis defer incom employe stock loss dispos properti equipment- impair charg equiti investment- lifo pension settlement- includ intang asset loss earli retir chang oper asset liabil account merchandis prepaid expens account payabl accru expens incom net cash provid use oper activ continu net cash provid use oper activ discontinu net cash provid use oper invest activitiescapit acquir compani net cash proce sale properti equipment- equiti proce sale business- purchas invest secur avail sale- net cash provid use invest activ continu net cash provid use invest activ discontinu ops- net cash provid use invest financ activitiesborrow revolv securit credit purchas treasuri payment premium earli retir debt- defer financ cost other- exercis warrants- exercis stock dividend common purchas cap call net cash provid use financ activ continu net cash provid use financ activ discontinu op net cash provid use financ increas cash cash cash equival begin cash equival end fiscal year end septemb cowen
use five-year discount cash flow analysi primari valuat method
deriv price target gener assum discount rate may appli
appropri adjust depend compani and/or industri specif factor also
assum termin growth rate depend long-term view specif
sub-industri coverag note discount rate assumpt could view
conserv rel actual weight averag cost capit view
assumpt reason long run lower discount rate assumpt
increas termin growth rate assumpt would lead higher estim valu
per share secondari measur look forward price-to-earnings multipl ev/sal ratio
impli dcf analysi compar histor averag
potenti risk associ drug distribut space industri
highli competit could pressur margin core drug distribut busi
current wave drug patent expir posit impact profit
deriv gener expect taper significantli next sever year
specialti provid signific tailwind industri concern
around sustain high growth biotech sector longer term
impact ppaca expect increas volum could subdu depend
implement execut
number company-specif risk associ pt includ credibl
indic enter pharma suppli chain sharp unexpect declin
gener deflat less expect benefit wbad econodisc
author research report herebi certifi view express research report accur reflect person view subject
secur issuer ii part compens relat directli indirectli specif recommend view express report
cowen compani llc affili make market stock secur
cowen compani llc compens research analyst activ servic intend benefit firm investor client individu compens determin research
analyst includ author report base varieti factor includ overal profit firm total revenu deriv sourc includ
revenu invest bank sale trade princip trade revenu cowen compani llc compens research analyst base specif invest
bank transact specif sale trade princip trade revenu
research report simultan avail client client websit research report client research report dissemin e-mail
made avail third-parti aggreg cowen compani llc respons redistribut research third parti aggreg select research report
avail print form addit electron form publish research report obtain firm client websit http //cowenlibrari bluematrix com/client/
inform opinion estim forecast date report subject chang without prior notif seek updat research appropri
variou regul may prevent us research report publish irregular interv appropri analyst judgement
inform subject secur may obtain offic research report publish sole inform purpos constru offer
sell solicit offer buy secur state offer solicit would illeg disclosur relat cowen compani llc
